Immunosuppression in Patients with High-Grade Gliomas Treated with Radiation and Temozolomide

Stuart A. Grossman, Xiaobu Ye, Glenn J. Lesser, Andrew E. Sloan, Hetty E. Carraway, Serena Desideri, Steven Piantadosi

Clinical Cancer Research · 2011 · 568 citations · 35 references

DOIFull text

Open access

Concepts

TL;DR

High‑grade glioma patients routinely receive radiation, temozolomide, and glucocorticoids, all of which are immunosuppressive. The study prospectively followed CD4 counts to determine whether low counts were linked to adverse outcomes. In a multicenter cohort of 96 newly diagnosed HGG patients, CD4 counts were measured before therapy and monthly for one year, alongside data on hospitalizations, infections, glucocorticoid use, survival, and cause of death. CD4 counts dropped to a nadir 2 months after therapy initiation, with 73 % below 300 cells/mm³ and 40 % below 200 cells/mm³, and patients with counts <200 at 2 months had significantly shorter survival (median 13.1 vs 19.7 months, HR 1.66), while most deaths were due to disease progression.

Abstract

Patients with high-grade gliomas (HGG) routinely receive radiation, temozolomide, and glucocorticoids. As each of these is immunosuppressive, we conducted a prospective, multicenter study to follow CD4 counts over time and determine whether low CD4 counts were associated with adverse outcomes.Patients with newly diagnosed HGG had CD4 counts drawn before initiating standard therapy and monthly thereafter for 1 year. Information on hospitalizations, infections, glucocorticoid use, survival, and cause of death were also collected.Ninety-six evaluable patients were accrued [85% glioblastoma, median age of 57, median Karnofsky performance status (KPS) = 90]. The median CD4 count before radiation and temozolomide treatment was 664 cells/mm(3). The CD4 count nadir occurred 2 months after initiating therapy when 73% of patients had CD4 counts less than 300 cells/mm(3) and 40% had less than 200 cells/mm(3). CD4 counts remained low throughout the year of follow-up. Patients with CD4 counts less than 200 cells/mm(3)at 2 months had shorter survival than those with higher counts (median: 13.1 vs. 19.7 months, P = 0.002). Median survival was related to CD4 toxicity grades (I = 23.8 months, II = 19.7 months, III-IV = 13.1 months, P = 0.009). The adjusted HR for death attributable to 2-month CD4 count below 200 was 1.66 (P = 0.03). Eighty-eight percent of deaths resulted from disease progression, whereas only 2.5% were due to infection.Severe reductions in CD4 counts in patients with newly diagnosed HGG treated with radiation and temozolomide treatment are common, treatment-related, long-lasting, and associated with early death from tumor progression.

References

35